Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Ted Rogers Centre for Heart Research · Paul Langerhans Institute Dresden · +17 more institutions
Indexed incrossref
Abstract
Establishing cardiovascular safety of new therapies for type 2 diabetes is important. Safety data are available for the subcutaneous form of the glucagon-like peptide-1 receptor agonist semaglutide but are needed for oral semaglutide.
Citation impact
1,884
total citations
- FWCI
- 136.60
- Percentile
- 100%
- References
- 26
Citations per year
Authors
15- MHMansoor HusainCorresponding
Ted Rogers Centre for Heart Research
- ALAndreas L. Birkenfeld
Paul Langerhans Institute Dresden, Helmholtz Zentrum München, Technische Universität Dresden, German Center for Diabetes Research, Deutsches Diabetes-Zentrum e.V., King's College London, Heinrich Heine University Düsseldorf, King's College - North Carolina
- MDMorten Donsmark
Novo Nordisk (Denmark)
- KDKathleen Dungan
The Ohio State University
- FGFreddy G. Eliaschewitz
DASA (Brazil)
Topics & keywords
Topics
Keywords
- Semaglutide
- Type 2 diabetes
- Medicine
- Diabetes mellitus
- Internal medicine
- Cardiology
- Endocrinology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.